Ken Griffin Biotechnology

Citadel Advisors LLC

  • $509 Billion
  • Q1 2025

Stock List

Stock Option Type Value Options Held Last Trade Trade History
KYMR
Kymera Therapeutics, Inc.
PUT
$120,000
4.4K
Q1 2025
Reduced 95.72%
CMRX
Chimerix Inc
PUT
$119,000
14K
Q1 2025
Reduced 88.62%
COGT
Cogent Biosciences, Inc.
PUT
$118,000
19.8K
Q1 2025
Added 401.41%
TSVT
2seventy Bio, Inc.
CALL
$117,000
23.8K
Q4 2024
Added 10428.21%
AUTL
Autolus Therapeutics PLC
PUT
$117,000
75.9K
Q1 2025
Reduced 41.7%
ANVS
Annovis Bio, Inc.
PUT
$115,000
76.7K
Q4 2024
Added 109.57%
INMB
Inmune Bio, Inc.
CALL
$115,000
14.8K
Q1 2025
Added 94.48%
PEPG
Pep Gen Inc.
PUT
$113,000
80.8K
Q1 2025
Reduced 22.22%
ALDX
Aldeyra Therapeutics, Inc.
PUT
$112,000
19.6K
Q4 2024
Added 58.15%
PLX
Protalix Bio Therapeutics, Inc.
PUT
$112,000
43.8K
Q1 2025
Reduced 98.07%
NVCT
Nuvectis Pharma, Inc.
PUT
$109,000
11.2K
Q1 2025
New holding
ALLO
Allogene Therapeutics, Inc.
CALL
$108,000
74.4K
Q1 2025
Added 90.75%
DNLI
Denali Therapeutics Inc.
PUT
$107,000
7.9K
Q1 2025
Added 40.94%
ENOB
Enochian Biosciences Inc
PUT
$107,000
23.3K
Q1 2025
New holding
FDMT
4 D Molecular Therapeutics, Inc.
PUT
$106,000
32.9K
Q1 2025
Reduced 45.26%
SVRA
Savara Inc
CALL
$106,000
38.5K
Q1 2025
Added 190.67%
HRTX
Heron Therapeutics, Inc.
PUT
$104,000
47.7K
Q1 2025
New holding
IMNM
Immunome Inc.
CALL
$104,000
15.6K
Q1 2025
Added 254.77%
GLUE
Monte Rosa Therapeutics, Inc.
PUT
$103,000
22.4K
Q4 2024
Reduced 32.84%
SCPH
Sc Pharmaceuticals Inc.
CALL
$102,000
38.9K
Q1 2025
New holding
URGN
Uro Gen Pharma Ltd.
PUT
$102,000
9.3K
Q1 2025
Reduced 17.09%
EDIT
Editas Medicine, Inc.
PUT
$101,000
87.4K
Q1 2025
Reduced 87.35%
ANNX
Annexon, Inc.
PUT
$100,000
52.1K
Q1 2025
Reduced 50.37%
PLX
Protalix Bio Therapeutics, Inc.
CALL
$99,000
39K
Q1 2025
Reduced 98.07%
AMLX
Amylyx Pharmaceuticals, Inc.
CALL
$98,000
27.8K
Q1 2025
Added 39.94%
BMEA
Biomea Fusion, Inc.
CALL
$98,000
46.3K
Q1 2025
Reduced 59.47%
MRVI
Maravai Lifesciences Holdings, Inc.
CALL
$97,000
44K
Q1 2025
Added 4997.03%
CDXC
Chroma Dex Corp.
PUT
$97,000
14.1K
Q1 2025
Added 301.65%
PBYI
Puma Biotechnology, Inc.
CALL
$96,000
32.7K
Q4 2024
Added 2214.2%
REPL
Replimune Group, Inc.
CALL
$94,000
9.7K
Q1 2025
Reduced 83.31%
BMEA
Biomea Fusion, Inc.
PUT
$93,000
43.9K
Q1 2025
Reduced 59.47%
DAWN
Day One Biopharmaceuticals, Inc.
CALL
$93,000
11.8K
Q1 2025
Added 119.04%
NRIX
Nurix Therapeutics, Inc.
PUT
$93,000
7.9K
Q1 2025
Added 54.72%
ABUS
Arbutus Biopharma Corp
PUT
$89,000
25.6K
Q1 2025
Reduced 45.45%
VERV
Verve Therapeutics, Inc.
PUT
$85,000
18.6K
Q1 2025
Added 141.08%
FDMT
4 D Molecular Therapeutics, Inc.
CALL
$83,000
25.8K
Q1 2025
Reduced 45.26%
CVAC
Cure Vac N.V.
CALL
$83,000
30.1K
Q3 2024
Added 288.26%
RLAY
Relay Therapeutics, Inc.
PUT
$83,000
31.7K
Q1 2025
Reduced 50.9%
SAGE
Sage Therapeutics, Inc.
PUT
$83,000
10.5K
Q1 2025
Added 1144.28%
VNDA
Vanda Pharmaceuticals Inc.
CALL
$83,000
18.2K
Q1 2025
Reduced 34.89%
RGNX
Regenxbio Inc.
CALL
$81,000
11.4K
Q1 2025
Added 75.52%
APLT
Applied Therapeutics Inc.
PUT
$80,000
165K
Q4 2024
Added 105.84%
PDSB
Pds Biotechnology Corp
CALL
$80,000
67.9K
Q4 2024
Added 91.52%
THRD
Third Harmonic Bio, Inc.
PUT
$79,000
22.8K
Q1 2025
Added 27.45%
MREO
Mereo Biopharma Group PLC
PUT
$78,000
34.7K
Q1 2025
Added 9.46%
CMPX
Compass Therapeutics, Inc.
CALL
$76,000
40.5K
Q3 2024
Reduced 76.01%
ENTA
Enanta Pharmaceuticals Inc
PUT
$76,000
13.9K
Q1 2025
Reduced 58.97%
GOSS
Gossamer Bio, Inc.
CALL
$75,000
68.4K
Q1 2025
Added 12.09%
TRDA
Entrada Therapeutics, Inc.
CALL
$74,000
8.2K
Q1 2025
Reduced 76.72%
Filter Shares Options
Ken Griffin

Ken Griffin

Ken Griffin is the founder and CEO of Citadel Advisors, a successful investment firm that uses technology and data-driven approaches to investing. Griffin is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.
Track Ken Griffin's portfolio
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email